

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: 7,078,511 Date Issued: July 18, 2006
Application Number: 08/765,108 Filed: March 27, 1997
Name of Patentee: Monty Krieger and Susan L. Acton
Title of Invention: *"Class BI and CI Scavenger Receptors"*

Commissioner for Patents
Office of Patent Publication
ATTN: Certificate of Correction Branch
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
DUE TO PTO'S ERRORS**

Sir:

Attached is form PTO/SB/44, which is suitable for printing.

In accordance with MPEP 1485, the exact page and/or claim and line number where errors occurred in the application file are discussed below.

LIST OF ERRORS IN THE PATENT

1. Claim 10, column 52 and 53, lines 58 through 2.
2. Claim 16, column 54, lines 21 through 27.

PTO'S ERRORS

In error 1, claim 10, column 52 and 53, lines 58 through 2, the claim was printed in error and should be "A method for screening for a compound which alters the binding of scavenger receptor protein type BI, which is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA molecule consisting of SEQ ID NO:3 or 7 and which

selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein in cell medium containing 10% serum, wherein the binding of acetylated low density lipoprotein to the scavenger receptor protein type BI is inhibited by native low density lipoprotein, comprising providing reagents for use in an assay for binding of low density lipoprotein or modified low density lipoprotein to the scavenger receptor protein the reagents comprising SR-BI, low density lipoprotein or modified low density lipoprotein, and means for determining if the low density lipoprotein or modified low density lipoprotein is bound to the scavenger receptor protein,

adding the compound to be tested to the assay, and

determining if the amount of modified low density lipoprotein or low density lipoprotein which is bound to the scavenger receptor protein is altered as compared to binding in the absence of the compound to be tested.” The requested correction to this claim can be attributed to the amendment filed on June 7, 2004, on page 3. (claim 44, renumbered as issued claim 10).

In error 2, claim 16, column 54, lines 21 through 27, the claim was printed in error and should be “A method for screening patients for abnormal scavenger receptor protein activity or function comprising

determining the presence of scavenger receptor protein type BI, wherein the scavenger receptor protein type BI is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-

paired double-stranded DNA molecule consisting of SEQ ID NO:3 or 7 and selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein, wherein the binding of acetylated low density lipoprotein to the scavenger receptor protein type BI is inhibited by native low density lipoprotein, and

determining if the quantity present or the function of the receptor is equivalent to that present in normal cells.” The requested correction to this claim can be attributed to the amendment filed on June 7, 2004, on page 5. (claim 50, renumbered as issued claim 16).

Correction of these errors does not involve such changes in the patent as would constitute new matter or would require re-examination.

Please issue a Certificate of Correction and send the document to:

Customer No. 23579
Patrea L. Pabst
Pabst Patent Group, LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, GA 30361

Applicants believe that no fees are required. However, should a fee be required,
the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-
3129.

Very truly yours,

PABST PATENT GROUP LLP

/Charles Vorndran/
Charles Vorndran, Ph.D., J.D.
Reg. No. 45,315

Date: April 1, 2008

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2153
(404) 879-2160 (Facsimile)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,078,511
APPLICATION NO.: 08/765,108
ISSUE DATE : July 18, 2006
INVENTOR(S) : Monty Krieger and Susan L. Acton

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 10, column 52 and 53, lines 58 through 2, replace claim 10 with --A method for screening for a compound which alters the binding of scavenger receptor protein type BI, which is encoded by a nucleotide molecule hybridizing to SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA molecule consisting of SEQ ID NO:3 or 7 and which selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein in cell medium containing 10% serum, wherein the binding of acetylated low density lipoprotein to the scavenger receptor protein type BI is inhibited by native low density lipoprotein, comprising
providing reagents for use in an assay for binding of low density lipoprotein or modified low density lipoprotein to the scavenger receptor protein comprising SR-BI, low density lipoprotein or modified low density lipoprotein, and means for determining if the low density lipoprotein or modified low density lipoprotein is bound to the scavenger receptor protein,
adding the compound to be tested to the assay, and
determining if the amount of modified low density lipoprotein or low density lipoprotein which is bound to the scavenger receptor protein is altered as compared to binding in the absence of the compound to be tested.--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pabst Patent Group LLP
1201 Peachtree Street, Suite 1200
Atlanta, Georgia 30361
United States of America

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,078,511
APPLICATION NO.: 08/765,108
ISSUE DATE : July 18, 2006
INVENTOR(S) : Monty Krieger and Susan L. Acton

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 16, column 54, lines 21 through 27, replace claim 16 with --A method for screening patients for abnormal scavenger receptor protein activity or function comprising
determining the presence of scavenger receptor protein type BI, wherein the scavenger receptor protein type BI is encoded by a nucleotide molecule hybridizing to
SEQ ID Nos. 3 and 7 under moderately stringent hybridization conditions at a temperature of approximately 25°C below the melting temperature of a perfectly base-paired double-stranded DNA molecule consisting of
SEQ ID NO:3 or 7 and selectively binds to low density lipoprotein and to modified lipoprotein having the characteristics of acetylated low density lipoprotein, wherein the binding of acetylated low density lipoprotein to the scavenger receptor protein type BI is inhibited by native low density lipoprotein, and
determining if the quantity present or the function of the receptor is equivalent to that present in normal cells.--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pabst Patent Group LLP
1201 Peachtree Street, Suite 1200
Atlanta, Georgia 30361
United States of America

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.